Yoshihide Ohba
About Yoshihide Ohba
Yoshihide Ohba is the Senior Director of the Cardiovascular Franchise at Bristol-Myers Squibb, with extensive experience in cardiovascular product marketing and strategic operations within the pharmaceutical industry.
Current Role at Bristol-Myers Squibb
Yoshihide Ohba currently serves as the Senior Director of the Cardiovascular Franchise at Bristol-Myers Squibb. He has been leading this franchise since November 2014. His role involves overseeing the strategic direction and operational management of the cardiovascular portfolio, ensuring the franchise's growth and development in the competitive pharmaceutical market.
Previous Positions at Bristol-Myers Squibb
Before his current role, Yoshihide Ohba held several key positions at Bristol-Myers Squibb. He was the Senior Product Manager for Eliquis from 2013 to 2014, and he worked as the Director of Strategic Operation in the President's Office for seven months in 2012 based in Tokyo. These roles equipped him with valuable insights and skills in product management and strategic operations.
Career at Boehringer Ingelheim
Between 2000 and 2012, Yoshihide Ohba had a distinguished career at Boehringer Ingelheim. He started as a Manager in the Cardiovascular Department, Marketing Division (Micardis group), serving for eight years. He then managed the New Pipeline Product Department from 2008 to 2009. From 2010 to 2012, he was the Head of Prazaxa Product Marketing. These roles underscore his extensive experience in cardiovascular product marketing.
Educational Background
Yoshihide Ohba completed a Bachelor's degree in Biology, General from Mie University, where he studied from 1989 to 1993. His foundational education in biology has likely contributed to his understanding of pharmaceutical sciences and product development, aiding his success in various roles in the pharmaceutical industry.
Experience in Cardiovascular Product Marketing
Yoshihide Ohba has extensive experience in the cardiovascular product marketing sector. He has managed several significant cardiovascular products, including Prazaxa at Boehringer Ingelheim and Eliquis at Bristol-Myers Squibb. His experience spans over a decade, during which he has played key roles in marketing strategies and product management, making substantial contributions to the pharmaceutical industry.